CoChat

Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment

Mattsson, Niklas, Portelius, Erik, Rolstad, Sindre, Gustavsson, Mikael, Andreasson, Ulf, Stridsberg, Mats, Wallin, Anders, Blennow, Kaj, Zetterberg, Henrik · 2012 · Journal of Alzheimer's Disease
Cited by 76

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Cerebrospinal fluid (CSF) measurements of amyloid-β42 (Aβ42), total-tau (T-tau), and phosphorylated tau (P-tau) may be used to predict future Alzheimer's disease (AD) dementia in patients with mild cognitive impairment (MCI). The precise temporal development of these biomarkers in relation to clinical progression is unclear. Earlier studies have been hampered by short follow-up. In an MCI cohort, we selected 15 patients who developed AD (MCI-AD) and 15 who remained cognitively stable during 4 years of follow-up. CSF was sampled at three serial occasions from each patient and analyzed for Aβ peptides, the soluble amyloid-β protein precursor protein fragments sAβPPα and sAβPPβ, T-tau, P-tau, and chromogranin B, which is a protein linked to regulated neuronal secretion. We also measured, for the first time in MCI patients, an extended panel of Aβ peptides by matrix-assisted-laser-desorption/ionization time-of-flight mass spectrometry (MS). Most biomarkers were surprisingly stable over the four years with coefficients of variation below or close to 10%. However, MCI-AD patients decreased in CSF AβX₋₄₀ and chromogranin B concentrations, which may indicate a reduced number of functional neurons or synapses with disease progression. The MS Aβ peptide panel was more useful than any single Aβ peptide to identify MCI-AD patients already at baseline. Knowledge on these biomarkers and their trajectories may facilitate early diagnosis of AD and be useful in future clinical trials to track effects of disease modifying drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-2012-120019

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 76

Metadata

Authors
Mattsson, N., Portelius, E., Rolstad, S., Gustavsson, M., Andreasson, U., Stridsberg, M., Wallin, A., Blennow, K., & Zetterberg, H.
Venue
Journal of Alzheimer's Disease
Published
2012-06-18
Volume
30
Issue
4
Pages
767-778
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W1594504409
Cited by
76
References
18
FWCI
8.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment. https://app.cochat.ai/papers/10.3233/jad-2012-120019
The paper
Mattsson, N., Portelius, E., Rolstad, S., Gustavsson, M., Andreasson, U., Stridsberg, M., Wallin, A., Blennow, K., & Zetterberg, H. (2012). Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2012-120019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.